ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in St Louis, MO

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Neoplasm Metastasis
Cognitive Dysfunction

Multiple Sclerosis (MS) trials near St Louis, MO, USA:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Saint Louis, Missouri, United States and 73 other locations

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Best Available Therapy (BAT)

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Saint Louis, Missouri, United States and 19 other locations

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...

Active, not recruiting
Multiple Sclerosis (MS)
Drug: Ocrelizumab
Drug: rHuPH20

Phase 1

Roche
Roche

Saint Louis, Missouri, United States and 20 other locations

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 ...

Not yet enrolling
Non-Active Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Drug: Interleukin-2
Drug: IDP-023

Phase 1

Indapta Therapeutics

Saint Louis, Missouri, United States and 3 other locations

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (FUSION)

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

Phase 2

Biogen
Biogen

Saint Louis, Missouri, United States and 76 other locations

Locations recently updated

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...

Enrolling
Relapsing Multiple Sclerosis
Drug: Placebo
Drug: Obexelimab

Phase 2

Zenas BioPharma

Saint Louis, Missouri, United States and 27 other locations

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) (Operetta 2)

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: Ocrelizumab
Drug: Fingolimod

Phase 3

Roche
Roche

Saint Louis, Missouri, United States and 111 other locations

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Saint Louis, Missouri, United States and 220 other locations

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis (CLOCK-MS)

system (CNS) and blood biomarkers relevant in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS...

Active, not recruiting
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Drug: Cladribine

Phase 4

The Washington University
The Washington University

Saint Louis, Missouri, United States and 4 other locations

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS...

Active, not recruiting
Multiple Sclerosis
Drug: RPC-1063

Phase 3

Celgene
Celgene

Saint Louis, Missouri, United States and 60 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems